Sponsor Deadline
Posted: 4/18/2022

Drug Transport Across the Blood-Testis and Blood-Epididymal Barriers (R61/R33 - Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to support in vivo research to elucidate the chemical features of non-native molecules that facilitate passage across the blood-testis and/or blood-epidydimal barriers.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): November 27, 2018, November 27, 2019, November 27, 2020

​PAR-18-853 Expiration Date November 28, 2020

Amount Description

The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.